Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

被引：0
|
作者：
P. G. Corrie
W. Qian
B. Basu
J. W. Valle
S. Falk
C. lwuji
H. Wasan
D. Palmer
M. Scott-Brown
J. Wadsley
S. Arif
J. Bridgewater
D. Propper
R. Gillmore
A. Gopinathan
R. Skells
P. Bundi
R. Brais
K. Dalchau
L. Bax
A. Chhabra
A. Machin
A. Dayim
K. McAdam
S. Cummins
L. Wall
R. Ellis
A. Anthoney
J. Evans
Y. T. Ma
C. Isherwood
A. Neesse
D. Tuveson
D. I. Jodrell
机构：
[1] Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s Hospital),Gastroenterology and Gastrointestinal Cancer Clinic
[2] Cancer Research UK—Cambridge Institute,undefined
[3] University of Cambridge,undefined
[4] University of Manchester and The Christie NHS Foundation Trust,undefined
[5] Bristol Haematology and Oncology Centre,undefined
[6] Leicester Royal Infirmary,undefined
[7] Hammersmith Hospital,undefined
[8] Imperial College,undefined
[9] Clatterbridge Cancer Centre,undefined
[10] University Hospital Coventry and Warwickshire,undefined
[11] Weston Park Hospital,undefined
[12] Velindre Cancer Centre,undefined
[13] UCL Cancer Institute,undefined
[14] Barts Cancer Institute,undefined
[15] The Royal Free Hospital,undefined
[16] Peterborough City Hospital,undefined
[17] Royal Surrey County Hospital,undefined
[18] Western General Hospital,undefined
[19] Royal Cornwall Hospitals,undefined
[20] St. James’s University Hospitals,undefined
[21] Beatson West of Scotland Cancer Centre,undefined
[22] University of Glasgow,undefined
[23] Queen Elizabeth Hospital,undefined
[24] University of Göttingen,undefined
[25] Cold Spring Harbor Laboratory,undefined
来源：
British Journal of Cancer | 2020年 / 122卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1760 / 1768
页数：8
相关论文
共 50 条
  • [1] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    Corrie, P. G.
    Qian, W.
    Basu, B.
    Valle, J. W.
    Falk, S.
    Iwuji, C.
    Wasan, H.
    Palmer, D.
    Scott-Brown, M.
    Wadsley, J.
    Arif, S.
    Bridgewater, J.
    Propper, D.
    Gillmore, R.
    Gopinathan, A.
    Skells, R.
    Bundi, P.
    Brais, R.
    Dalchau, K.
    Bax, L.
    Chhabra, A.
    Machin, A.
    Dayim, A.
    McAdam, K.
    Cummins, S.
    Wall, L.
    Ellis, R.
    Anthoney, A.
    Evans, J.
    Ma, Y. T.
    Isherwood, C.
    Neesse, A.
    Tuveson, D.
    Jodrell, D., I
    BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1760 - 1768
  • [2] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Pat Gulhati
    Laura Prakash
    Matthew H. G. Katz
    Xuemei Wang
    Milind Javle
    Rachna Shroff
    David Fogelman
    Jeffrey E. Lee
    Ching-Wei D. Tzeng
    Jeffrey H. Lee
    Brian Weston
    Eric Tamm
    Priya Bhosale
    Eugene J. Koay
    Anirban Maitra
    Huamin Wang
    Robert A. Wolff
    Gauri R. Varadhachary
    Annals of Surgical Oncology, 2019, 26 : 619 - 627
  • [3] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind
    Shroff, Rachna
    Fogelman, David
    Lee, Jeffrey E.
    Tzeng, Ching-Wei D.
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric
    Bhosale, Priya
    Koay, Eugene J.
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 619 - 627
  • [4] Efficacy and safety of sintilimab combined nab-paclitaxel and gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC): A retrospective analysis
    Wang, J.
    He, Y.
    Lv, H.
    Chen, B.
    Nie, C.
    Xu, W.
    Zhao, J.
    Zhang, B.
    Cheng, X.
    Li, Q.
    Tu, S.
    Chen, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S247 - S247
  • [5] Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Kotasek, Dusan
    Nagrial, Adnan
    Lumba, Sumit
    Tebbutt, Niall C.
    George, Thomas J.
    Smith, Sheri Lynn
    Gagnon, Suzanne
    Cullen, Michael T.
    Walker, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
  • [7] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [8] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [9] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
    Tempero, M.
    Oh, D-Y
    Tabernero, J.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D-T
    Starling, N.
    Bachet, J-B
    Chang, H-M
    Maurel, J.
    Garcia-Carbonero, R.
    Lonardi, S.
    Coussens, L. M.
    Fong, L.
    Tsao, L. C.
    Cole, G., Jr.
    James, D.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 600 - 608
  • [10] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
12345